The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Open accessAbstract
Cancer is one of the major causes of death worldwide and chemotherapy is a major therapeutic approach for the treatment which may be used alone or combined with other forms of therapy. However, conventional chemotherapy suffers lack of aqueous solubility, lack of selectivity and multidrug resistance. Nanotherapeutics is rapidly progressing aimed to solve several limitations of conventional drug delivery systems. Nonspecific target of cancer chemotherapy leads to damage rapidly proliferating normal cells and can be significantly reduced through folate and transferrin mediated nanotherapeutics which are aimed to target cancerous cells. Multidrug resistance is challenge in cancer chemotherapy which can be significantly reversed by solid lipid nanoparticles, polymeric nanoparticles, mesoporous silica nanoparticles, nanoparticulated chemosensitizer, nanoparticluated poloxamer and magnetic nanoparticles. Hydrophobic nature of chemotherapeutics leads to poor aqueous solubility and low bioavailability which can be overcome by nanocrystals, albumin based nanoparticles, liposomal formulation, polymeric micelles, cyclodextrin and chitosan based nanoparticles. This review focuses the role of nanotherapeutics to overcome lack of selectivity, multidrug resistance and lack of aqueous solubility of conventional cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Triblock Copolymer Syntheses of Mesoporous Silica with Periodic 50 to 300 Angstrom Pores
Zhao, D., Feng, J., Huo, Q., Melosh, N., Fredrickson, G. H., Chmelka, B. F., & Stucky, G. D. (1998) · Science · doi:10.1126/science.279.5350.548 · Cited by 11,753
A new family of mesoporous molecular sieves prepared with liquid crystal templates
Beck, J. S., Vartuli, J. C., Roth, W. J., Leonowicz, M. E., Kresge, C. T., Schmitt, K. D., Chu, C. T. W., Olson, D. H., Sheppard, E. W., McCullen, S. B., et al. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00053a020 · Cited by 10,967
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Nanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Cited by
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
PLGA-Based Nanoparticles in Cancer Treatment
Rezvantalab, S., Drude, N. I., Moraveji, M. K., Güvener, N., Koons, E. K., Shi, Y., Lammers, T., & Kiessling, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01260 · Cited by 607
Magnetic Nanoparticles in Cancer Therapy and Diagnosis
Farzin, A., Etesami, S. A., Quint, J., Memic, A., & Tamayol, A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901058 · Cited by 562
Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids
Wang, Q., Zhuang, X., Mu, J., Deng, Z.-B., Jiang, H., Zhang, L., Xiang, X., Wang, B., Yan, J., Miller, D., et al. (2013) · Nature Communications · doi:10.1038/ncomms2886 · Cited by 525
Gidwani, B., & Vyas, A. (2015) · BioMed Research International · doi:10.1155/2015/198268 · Cited by 473
Figueiredo, P., Lintinen, K., Kiriazis, A., Hynninen, V., Liu, Z., Bauleth-Ramos, T., Rahikkala, A., Correia, A., Kohout, T., Sarmento, B., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.034 · Cited by 398
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Nanotechnology-based approaches in anticancer research
Kamal, M. A., Jabir NR, N., Tabrez, Ashraf, Shakil, & Damanhouri (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33838 · Cited by 363
2D MoS2‐Based Nanomaterials for Therapeutic, Bioimaging, and Biosensing Applications
Yadav, V., Roy, S., Singh, P., Khan, Z., & Jaiswal, A. (2019) · Small · doi:10.1002/smll.201803706 · Cited by 361
Prasad, M., Lambe, U. P., Brar, B., Shah, I., J, M., Ranjan, K., Rao, R., Kumar, S., Mahant, S., Khurana, S. K., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.026 · Cited by 327
Debele, T. A., Mekuria, S. L., & Tsai, H.-C. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.05.121 · Cited by 317
Di Bella, M. A. (2022) · Biology · doi:10.3390/biology11060804 · Cited by 304
Rafiei, P., & Haddadi, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121881 · Cited by 284
Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells
Safwat, M. A., Soliman, G. M., Sayed, D., & Attia, M. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.076 · Cited by 109
Roshani, M., Rezaian-Isfahni, A., Lotfalizadeh, M. H., Khassafi, N., Abadi, M. H. J. N., & Nejati, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03115-1 · Cited by 84
Badparvar, F., Marjani, A. P., Salehi, R., & Ramezani, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-57296-4 · Cited by 48
Lee, C.-S., Kim, T., Oh, D., Bae, S., Ryu, J., Kong, H., Jeon, H., Seo, H., Jeon, S., & Kim, T. (2020) · Cancers · doi:10.3390/cancers12030634 · Cited by 46
Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles
Wang, Y., Shi, W., Song, W., Wang, L., Liu, X., Chen, J., & Huang, R. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm32398b · Cited by 46
Bridging machine learning and peptide design for cancer treatment: a comprehensive review
Rezaee, K., & Eslami, H. (2025) · Artificial Intelligence Review · doi:10.1007/s10462-025-11148-3 · Cited by 34
Metadata
- Authors
- Chidambaram, M., Manavalan, R., & Kathiresan, K.
- Venue
- Journal of Pharmacy & Pharmaceutical Sciences
- Publisher
- Frontiers Media SA
- Published
- 2011-02-16
- Volume
- 14
- Issue
- 1
- Pages
- 67
- ISSN
- 1482-1826 (ISSN-L)
- OpenAlex
- W1571365882
- Cited by
- 566
- References
- 85
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.